Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Myriad Genetics, Inc. (NASDAQ: MYGN) was $25.25 for the day, up 5.43% from the previous closing price of $23.95. In other words, the price has increased by $5.43 from its previous closing price. On the day, 1.09 million shares were traded. MYGN stock price reached its highest trading level at $25.28 during the session, while it also had its lowest trading level at $23.6712.
Ratios:
Our analysis of MYGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.82 and its Current Ratio is at 1.99. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on May 08, 2024, Upgraded its rating to Outperform and sets its target price to $35 from $25 previously.
On December 19, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on December 19, 2023, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 01 ’23 when Riggsbee Richard Bryan sold 30,000 shares for $19.09 per share. The transaction valued at 572,835 led to the insider holds 291,812 shares of the business.
Riggsbee Richard Bryan sold 30,000 shares of MYGN for $470,622 on Nov 01 ’23. The Chief Financial Officer now owns 321,812 shares after completing the transaction at $15.69 per share. On Jun 02 ’23, another insider, SPIEGELMAN DANIEL K, who serves as the Director of the company, sold 8,638 shares for $23.01 each. As a result, the insider received 198,760 and left with 40,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 2284577280 and an Enterprise Value of 2209975040. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.93 while its Price-to-Book (P/B) ratio in mrq is 3.01. Its current Enterprise Value per Revenue stands at 2.855 whereas that against EBITDA is -35.76.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.96, which has changed by 0.36389518 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $24.21, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 22.31%, while the 200-Day Moving Average is calculated to be 32.50%.
Shares Statistics:
MYGN traded an average of 697.38K shares per day over the past three months and 1001940 shares per day over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 86.02M. Insiders hold about 4.29% of the company’s shares, while institutions hold 102.31% stake in the company. Shares short for MYGN as of 1713139200 were 5499648 with a Short Ratio of 7.89, compared to 1710460800 on 4802769. Therefore, it implies a Short% of Shares Outstanding of 5499648 and a Short% of Float of 8.520000399999999.
Earnings Estimates
The current assessment of Myriad Genetics, Inc. (MYGN) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.01 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.05, while EPS last year was -$0.08. The consensus estimate for the next quarter is $0.02, with high estimates of $0.07 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.05 and $0.0 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.24, with 11.0 analysts recommending between $0.37 and $0.1.
Revenue Estimates
For the next quarter, 12 analysts are estimating revenue of $208.27M. There is a high estimate of $212.31M for the next quarter, whereas the lowest estimate is $201.1M.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $837M, while the lowest revenue estimate was $823.25M, resulting in an average revenue estimate of $830.39M. In the same quarter a year ago, actual revenue was $753.2MBased on 13 analysts’ estimates, the company’s revenue will be $893.71M in the next fiscal year. The high estimate is $914.32M and the low estimate is $866.9M.
